Please Wait
Applying Filters...
menu
    • menu
    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    Aarti Pharmalabs is a partner of choice for pharmaceutical companies for APIs & Intermediates. Largest Indian producer of Caffeine.

    Virtual Booth

    Contact Supplier

    Axplora is your partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Pemvidutide

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Altimmune Unveils 2025 Financial Results And Business Updates
    Altimmune Unveils 2025 Financial Results And Business Updates

    05 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/05/3250009/0/en/Altimmune-Announces-Fourth-Quarter-and-Full-year-2025-Financial-Results-and-Business-Updates.html

    GLOBENEWSWIRE
    05 Mar 2026
    Share Share
    Altimmune To Participate In Upcoming Investor Conferences
    Altimmune To Participate In Upcoming Investor Conferences

    02 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/02/3247264/0/en/Altimmune-to-Participate-in-Upcoming-Investor-Conferences.html

    GLOBENEWSWIRE
    02 Mar 2026
    Share Share
    Altimmune Completes $75M Common Stock Offering
    Altimmune Completes $75M Common Stock Offering

    29 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/29/3229184/0/en/Altimmune-Announces-Closing-of-75-Million-Registered-Direct-Offering-of-Common-Stock.html

    GLOBENEWSWIRE
    29 Jan 2026
    Share Share
    Altimmune Granted FDA Breakthrough Status For Pemvidutide In MASH
    Altimmune Granted FDA Breakthrough Status For Pemvidutide In MASH

    05 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/05/3212638/0/en/Altimmune-Receives-FDA-Breakthrough-Therapy-Designation-for-Pemvidutide-in-MASH.html

    GLOBENEWSWIRE
    05 Jan 2026
    Share Share
    Altimmune eyes phase 3 MASH trial as weight loss deepens
    Altimmune eyes phase 3 MASH trial as weight loss deepens

    19 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/19/3208385/0/en/Altimmune-Announces-that-Pemvidutide-Achieved-Key-Measures-of-Success-at-48-Weeks-in-IMPACT-Phase-2b-MASH-Trial.html

    GLOBENEWSWIRE
    19 Dec 2025
    Share Share
    Altimmune Poised For $1B+ Opportunity As MASH Drug Aces Phase IIb
    Altimmune Poised For $1B+ Opportunity As MASH Drug Aces Phase IIb

    13 Nov 2025

    // BIOSPACE

    https://www.biospace.com/drug-development/altimmune-poised-for-1b-opportunity-as-mash-drug-aces-phase-iib

    BIOSPACE
    13 Nov 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.